StockIQpro
NASDAQ:SLDB

Solid Biosciences Inc.

Track all markets on TradingView
Track all markets on TradingView

Solid Biosciences Inc. reported net income of −$174.3M in fiscal 2025. Free cash flow was −$157.4M, and the diluted share count rose 114.4%.Summary generated from Solid Biosciences Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−109.9%
Debt / equityn/a
Free cash flow−$157.4M
FCF marginn/a
Share count change+114.4%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue148n/an/an/a
Operating income−72−106−104−130−179
Net income−72−86−96−125−174
Free cash flow−79−101−96−101−157

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)